Navigation Links
Marshall Edwards Announces Name Change to MEI Pharma ("MEIP")
Date:6/28/2012

2012. The Company received approval of its IND application for ME-344 in April 2012 and a Phase I clinical trial of intravenous ME-344 in patients with solid refractory tumors is ongoing. For more information, go to www.marshalledwardsinc.com until July 1, 2012, thereafter www.meipharma.com.

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological chan
'/>"/>

SOURCE Marshall Edwards, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Marshall Edwards Announces First Cohort Of Patients Dosed In Phase I Clinical Trial Of Oncology Drug Candidate ME-344
2. Novogen Board Approves US$4 Million Investment In Marshall Edwards Rights Offering
3. Marshall Edwards Receives $4 Million Subscription From Novogen In Rights Offering
4. Access Pharmaceuticals Announces Positive Data From MuGard Phase 4 Clinical Trial In Oral Mucositis At MASCC/ISOO 2012 Symposium
5. Practice Fusion Announces $34 Million in Financing Led by Artis Ventures
6. BioDelivery Sciences Announces Positive Results from BEMA Buprenorphine/Naloxone (BNX) Pharmacokinetic Study
7. Detroit Metro Convention & Visitors Bureau announces launch of Medical Meetings Initiative; recruits top leaders to Advisory Council
8. DATATRAK Announces Accreditation Program
9. Golden Meditech Holdings Limited Announces 2011/ 2012 Annual Results
10. Global Information, Inc. Announces New Market Forecasts For Drug Discovery Industry as it Emerges from Recession
11. Omeros Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... -- Zimmer Holdings, Inc. (NYSE and SIX: ZMH) today ... 2014.  The Company reported second quarter net sales of ... constant currency over the second quarter of 2013.  Diluted ... and $1.49 adjusted, an increase of 4.2% adjusted over ... quarter was marked by solid sales growth in a ...
(Date:7/24/2014)... 24, 2014 Cognizant ... that it has been selected by ... with membership representation from 19 major pharmaceutical ... that will transform the way clinical sites ... TransCelerate BioPharma Inc. is dedicated to making ...
(Date:7/23/2014)... ALTO, Calif., July 23, 2014  Varian Medical Systems ... earnings of $1.02 per diluted share in the third ... impacted by about $0.06 per diluted share due to ... portion of Varian,s existing equity investment in Augmenix, a ... company-wide revenues totaled $748 million for the third quarter ...
Breaking Medicine Technology:Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 2Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 3Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 4Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 5Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 6Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 7Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 8Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 9Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 10Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 11Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 12Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 13Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 14Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 15Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 16Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 17Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 18Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 19Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 20Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 21Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 22Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 23Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 24TransCelerate Selects Cognizant to Develop a Clinical Trials Collaboration Platform 2TransCelerate Selects Cognizant to Develop a Clinical Trials Collaboration Platform 3TransCelerate Selects Cognizant to Develop a Clinical Trials Collaboration Platform 4TransCelerate Selects Cognizant to Develop a Clinical Trials Collaboration Platform 5Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 2Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 3Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 4Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 5Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 6Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 7Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 8Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 9
... LOUIS, Oct. 30 Stereotaxis received notice that the ... for distribution in the European market. The product ... on-going co-development agreement between Stereotaxis and Biosense Webster to ... the Niobe Magnetic Navigation System (MNS). , A ...
... COLUMBUS, Ohio, Oct. 29 Mettler-Toledo International Inc. (NYSE: MTD ) ... the highlights: , Sales in local currency declined by ... a 2% negative currency impact. , Net earnings ... in the third quarter of 2008. Adjusted EPS was $1.36, ...
Cached Medicine Technology:Stereotaxis Receives Notice of European Approval of an Additional Magnetic Irrigated Catheter 2Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 2Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 3Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 4Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 5Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 6Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 7Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 8Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 9Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 10Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 11Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 12Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 13
(Date:7/24/2014)... (PRWEB) July 24, 2014 The North American ... $1.6 billion in 2014, and is expected to register a ... U.S. has been the biggest market for the air and ... the U.S. market has witnessed budget cuts as well. , ... missile defense radar market report, to get an idea of ...
(Date:7/24/2014)... 23, 2014 (HealthDay News) -- Even though its use is ... as Tylenol -- does not help treat lower back pain, ... found the drug was no more effective than a dummy ... back pain. Besides showing no effect in easing discomfort, ... improving sleep woes tied to back pain, nor did it ...
(Date:7/24/2014)... at emergency departments can be reduced by enabling patients ... their doctor,s surgery. This is just one of several ... researchers at the University of Bristol. , Called ,Primary ... systematic reviews, the report has been compiled by researchers ... looked at evidence from studies around the world. They ...
(Date:7/24/2014)... and Rhode Island have identified two previously ... of laparoscopically adjustable gastric bands. Adding widespread ... the superolateral band margin by more than ... presence of an air-fluid,level above the band ... will aid them in diagnosing affected bariatric ...
(Date:7/24/2014)... were found commonly in streams throughout the Midwest, ... the first broad-scale investigation of neonicotinoid insecticides in ... first conducted within the United States. , Effective ... use of neonicotinoid insecticides has dramatically increased over ... in the Midwest. The use of clothianidin, ...
Breaking Medicine News(10 mins):Health News:North America Air and Missile Defense Radar Market is Expected to Reach $2.7 Billion in 2020 - New Report by MicroMarket Monitor 2Health News:North America Air and Missile Defense Radar Market is Expected to Reach $2.7 Billion in 2020 - New Report by MicroMarket Monitor 3Health News:North America Air and Missile Defense Radar Market is Expected to Reach $2.7 Billion in 2020 - New Report by MicroMarket Monitor 4Health News:Acetaminophen May Not Help Against Back Pain, Study Contends 2Health News:Acetaminophen May Not Help Against Back Pain, Study Contends 3Health News:Seeing the same GP at every visit will reduce emergency department attendance 2Health News:Corn & soy insecticides similar to nicotine found widespread in Midwest rivers -- USGS news 2
... to Create Sustainable Breast Cancer Programs in ... Countries with Highest Potential, Greatest Need, BUDAPEST, Hungary, ... receiving a breast cancer diagnosis each year, it has ... about this,life-threatening disease. Building on the U.S.-Middle East Partnership ...
... experts say , , FRIDAY, Sept. 28 (HealthDay News) -- ... autoimmune disease lupus is building up steam, a group ... researchers from across the United States spoke at a ... of the improving outlook for patients with systemic lupus ...
... According to the American Society of,Plastic ... Latinos received,physician-administered aesthetic procedures like BOTOX(R) Cosmetic ... board certified,dermatologist in Miami, says that given ... that women make informed decisions when,considering these ...
... TJ Enterprises, LLC,announced that its product, ... the treatment of baby digestive discomfort including ... the U.S. Food and Drug,Administration (FDA) confirmed ... a non-homeopathic gripe water, Apple Flavored Baby,s,Bliss, ...
... WAYNE, Pa., Sept. 28 Escalon Medical Corp.,(Nasdaq: ... quarter and,twelve months ended June 30, 2007. For ... increased,to $38,837,780 compared with $29,790,698 in fiscal 2006. This ... million lump sum settlement payment,from IntraLase Corp. to the ...
... NEW ORLEANS, Sept. 28 Sanarus Medical today ... select centers across,the country. These Centers, including breast ... partnership with Sanarus to,increase the awareness and availability ... benign breast tumors, known as,fibroadenomas. Sanarus will host ...
Cached Medicine News:Health News:Susan G. Komen for the Cure Launches Unprecedented Global Expansion Program in 10 Countries 2Health News:Susan G. Komen for the Cure Launches Unprecedented Global Expansion Program in 10 Countries 3Health News:Better Lupus Treatments on the Horizon 2Health News:Better Lupus Treatments on the Horizon 3Health News:Better Lupus Treatments on the Horizon 4Health News:After Infant Gripe Water Recall Scare, Homeopathic Medicine Offers Safe Alternative 2Health News:Escalon(R) Reports Financial Results for 2007 Fiscal Year 2Health News:Escalon(R) Reports Financial Results for 2007 Fiscal Year 3Health News:Escalon(R) Reports Financial Results for 2007 Fiscal Year 4Health News:Escalon(R) Reports Financial Results for 2007 Fiscal Year 5Health News:Escalon(R) Reports Financial Results for 2007 Fiscal Year 6Health News:Escalon(R) Reports Financial Results for 2007 Fiscal Year 7Health News:Sanarus Announces Partnership With Leading US Breast Care Physicians for the Next Generation Visica 2(TM) Treatment System for Fibroadenomas 2
... three styles. Each style has multiple sizes. ... popular style. Pectoral Implants are available non-sterile ... individually, not in pairs. Both styles are ... for a specific side and are directional. ...
... The IQmarkTM Diagnostic Workstation Software ... Software System that digitally stores many ... Designed with Microsofts open-architecture products in ... as EMR integration (using ActiveX controls), ...
... Digital ECG is a highly advanced and refined ... personal computer. Everything you need to get up ... and operating costs of the IQmark Digital ECG ... ECG machines (even including the cost of the ...
... Trichloroacetic acid (TCA) peels are often ... substantial discomfort. PCA Professional™ TCA peels are ... solutions are blends formulated with many ingredients ... plumping phytohormones and kojic and azelaic acids ...
Medicine Products: